Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of oral GKT137831 added to UDCA in primary biliary cholangitis
MOH_2018-01-03_001868Phase 2Not yet recruiting
- Sponsor
- Genkyotex
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setanaxib in primary biliary cholangitis (PBC) (3 arms), sponsored by Genkyotex. Primary endpoint: Change in gamma-glutamyl transferase. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
setanaxib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2018-01-03_001868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-03_001868.